US2020405818A1PendingUtilityA1

Treatment of short bowel syndrome patients with colon-in-continuity

79
Assignee: SHIRE NPS PHARMACEUTICALS INCPriority: Nov 1, 2004Filed: Sep 3, 2020Published: Dec 31, 2020
Est. expiryNov 1, 2024(expired)· nominal 20-yr term from priority
Inventors:Elizabeth L. SanguinettiThomas B. MarriottJennifer LopansriConsuelo M. Blosch
A61K 38/26A61P 1/00A61B 5/4222A61P 1/02A61K 9/0019
79
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating an adult human patient having short bowel syndrome with at least about 10% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state, who receives an amount of parenteral nutrition each week, and who presents with colon-in-continuity with remnant small intestine, said method comprising administering [Gly2]hGLP-2 to said patient using a dosing regimen effective to increase the endogenous GLP-2 in the fed state of said patient. 
     
     
         2 . The method as defined in  claim 1 , wherein the [Gly2]hGLP-2 is administered at a daily dose of from 30 to 150 μg/kg. 
     
     
         3 . The method as defined in  claim 1 , wherein said patient has at least about 15% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state. 
     
     
         4 . The method as defined in  claim 3 , wherein said patient has at least about 20% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state. 
     
     
         5 . The method as defined in  claim 4 , wherein said patient has at least about 25% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state. 
     
     
         6 . The method as defined in  claim 5 , wherein said patient has at least about 30% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state. 
     
     
         7 . The method as defined in  claim 6 , wherein said patient has at least about 35% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state. 
     
     
         8 . The method as defined in  claim 7 , wherein said patient has at least about 40% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state. 
     
     
         9 . The method as defined in  claim 8 , wherein said patient has at least about 45% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state. 
     
     
         10 . The method as defined in  claim 9 , wherein said patient has at least about 50% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state. 
     
     
         11 . The method as defined in  claim 10 , wherein said patient has at least about 55% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state. 
     
     
         12 . The method as defined in  claim 11 , wherein said patient has at least about 60% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state. 
     
     
         13 . The method as defined in  claim 12 , wherein said patient has at least about 65% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state. 
     
     
         14 . The method as defined in  claim 13 , wherein said patient has at least about 70% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state. 
     
     
         15 . The method as defined in  claim 14 , wherein said patient has at least about 80% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state. 
     
     
         16 . The method as defined in  claim 15 , wherein said patient has at least about 90% (as compared to a normal healthy individual) endogenous GLP-2 levels in the fed state. 
     
     
         17 . The method as defined in  claim 1 , wherein said patient produces at least about 10 pmol/L of endogenous GLP-2 levels in the fed state. 
     
     
         18 . The method as defined in  claim 17 , wherein said patient produces at least about 15 pmol/L of endogenous GLP-2 levels in the fed state. 
     
     
         19 . The method as defined in  claim 18 , wherein said patient produces at least about 20 pmol/L of endogenous GLP-2 levels in the fed state. 
     
     
         20 . The method as defined in  claim 19 , wherein said patient produces at least about 25 pmol/L of endogenous GLP-2 levels in the fed state. 
     
     
         21 . The method as defined in  claim 20 , wherein said patient produces at least about 30 pmol/L of endogenous GLP-2 levels in the fed state. 
     
     
         22 . The method as defined in  claim 21 , wherein said patient produces at least about 35 pmol/L of endogenous GLP-2 levels in the fed state. 
     
     
         23 . The method as defined in  claim 22 , wherein said patient produces at least about 40 pmol/L of endogenous GLP-2 levels in the fed state. 
     
     
         24 . The method as defined in  claim 23 , wherein said patient produces at least about 45 pmol/L of endogenous GLP-2 levels in the fed state. 
     
     
         25 . The method as defined in  claim 24 , wherein said patient produces at least about 50 pmol/L of endogenous GLP-2 levels in the fed state. 
     
     
         26 . The method as defined in  claim 25 , wherein said patient produces at least about 55 pmol/L of endogenous GLP-2 levels in the fed state. 
     
     
         27 . The method as defined in  claim 26 , wherein said patient produces at least about 60 pmol/L of endogenous GLP-2 levels in the fed state. 
     
     
         28 . The method as defined in  claim 27 , wherein said patient produces at least about 65 pmol/L of endogenous GLP-2 levels in the fed state. 
     
     
         29 . The method as defined in  claim 28 , wherein said patient produces at least about 70 pmol/L fed of endogenous GLP-2 levels in the fed state.

Join the waitlist — get patent alerts

Track US2020405818A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.